Frontline Treatment Options for Hodgkin's Lymphoma
Frontline Treatment Options for Hodgkin's Lymphoma
A 32-Year-Old Man with Stage IV Hodgkin's Lymphoma
- History & Physical:
- A 32-year-old man presented to his PCP in January 2017 complaining of abdominal pain, pruritus, fevers of over 101⁰ F, and weight loss
- Imaging
- PET scan showed avid mediastinal mass
- Labs
- HgB 12.2 g/dL
- WBC 7,500 mm2
- ALC 3,200 mm2
- Albumin 3.9 mg/dL
- ANC 4,200/mm3
- Liver and renal function tests WNL
- Biopsy confirmed mixed cellularity classical Hodgkin’s lymphoma (HL)
- Normal lung and cardiac function
- Final Staging: Stage IVB, cHL, IPS score 2
- ECOG PS 2
- He received 2 cycles of ABVD. PET/CT restaging showed Deauville (1-). He received 4 additional cycles of AVD
- He achieved a CR
- 2 years after completion of therapy, the patient complained of a persistent cough and fatigue
- PET/CT showed bilateral mediastinal masses
- Biopsy confirmed cHL
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Later-Line CD19 and Bispecific Therapies Considered After CAR T
October 1st 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Read More
Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL
September 16th 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More
